Contact Information

Biography

Carl A. Anderson joined the Â鶹ֱ²¥ faculty in 2002 as an assistant professor of pharmaceutical science. He is a founding member of the Â鶹ֱ²¥ Center for Pharmaceutical Technology (DCPT). His current focus is on building and leading a research group to explore new and existing analytical technologies and demonstrate their relevance to process analytical technology (PAT) applications. In addition to exploring PAT tools, his group uses these tools to enhance the understanding of the chemistry and physics of pharmaceutical technology. He has spent seven years working for the three different incarnations of the pharmaceutical company that became known as Aventis Pharmaceuticals. While there, he led the team that developed, validated, and implemented Aventis' first PAT based methods. He served on the executive committee of the NIR Validation Working Group (NIRVWoG) that authored the revisions to USP, and currently serves on the ASTM E55 committee as a member at large on the board of directors.

Education

  • Ph.D., Chemistry, The University of Texas at Austin, 1995
  • B.S., Chemistry, California State University-Fullerton, 1990

Profile Information

  • Pharmaceutical manufacturing, process analytical technology (PAT), quality by design (QbD) in the pharmaceutical industry, quality risk management systems, performance-based quality specifications (PBQS)

Patents:

2006 - Tunable laser-based chemical imaging system. (# US 7525654 B2)

2006 - Tunable laser-based process monitoring apparatus. (# US 7528950 B2)

2006 - Spectroscopic Pharmacy Verification and Inspection System. (# US 20050288906 A3)

Grants:

2015: Anderson, C. Bristol-Myers Squibb Graduate Student Fellowship, Principal Investigator, PRI-Bristol-Myers Squibb
Company.

2015: Anderson, C. & Drennen, J. K., A QbD approach to process development: Defining critical quality attributes, evaluating
criticality across scales, and relating variation in CPPs/CQAs to product performance, Co-Principal Investigator, GOV-Food &
Drug Administration (FDA).

2014: Anderson, C. Development of Training Module, Co-Principal Investigator, PRI-National Institute for Pharmaceutical
Technology and Education (NIPTE).

Publications:

Sameer, T., Roopwani, R., Buckner, I., Anderson, C., & Drennen, J. (in press, 2017). Determination of Spatially Resolved
Tablet Density and Hardness Using Near-Infrared Chemical Imaging (NIR-CI). Applied Spectroscopy.

Alam, M., Drennen, J., Shi, Z., & Anderson, C. (in press, 2017). In-line monitoring and optimization of powder flow in a
simulated continuous process using transmission near infrared spectroscopy. INT J PHARMACEUT.

Hanzhou, F., Anderson, C., Drennen, J., Bondi, R., & Igne, B. (in press, 2017). Investigation of the Sensitivity of Transmission
Raman Spectroscopy for Polymorphs Detection in Pharmaceutical Tablets. Applied Spectroscopy.

Presentations:

Anderson, C.
, Alam, A., Hossain, N., Igne, B., & Drennen, J. K. (2014). Pure Spectral Information to Improve Partial Least
Square (PLS) Model Performance: NIR Analysis of Pharmaceutical Compacts. SciX, Reno, Nevada.

Anderson, C., Drennen, J. K., Igne, B., Talwar, S., & Feng, H. (2014). NIR Spatially Resolved Spectroscopy for Tablet Quality
Determination. EURO Pact, Barcelona, Spain.

Anderson, C., Talwar, S., Roopwani, R., Buckner, I., & Drennen, J. (2013). Determination of Spatially Resolved Tablet Density
and Hardness using Near-Infrared based Chemical Imaging (NIR-CI) and Micro-Indentation: Utilizing NIR chemical Imaging for
physical analysis of pharmaceutical Samples. SciX, Milwaukee, Wisconsin.